echinocandin-b and Acute-Disease

echinocandin-b has been researched along with Acute-Disease* in 1 studies

Other Studies

1 other study(ies) available for echinocandin-b and Acute-Disease

Article	Year
Total synthesis and antifungal evaluation of cyclic aminohexapeptides. Bioorganic & medicinal chemistry, 2000, Volume: 8, Issue:7 The need for new therapies to treat systemic fungal infections continues to rise. Naturally occurring hexapeptide echinocandin B (1) has shown potent antifungal activity via its inhibition of the synthesis of beta-1,3 glucan, a key fungal cell wall component. Although this series of agents has been limited thus far based on their physicochemical characteristics, we have found that the synthesis of analogues bearing an aminoproline residue in the 'northwest' position imparts greatly improved water solubility (> 5 mg/mL). The synthesis and structure-activity relationships (SAR) based on whole cell and upon in vivo activity of the series of compounds are reported. Topics: Acute Disease; Amines; Amphotericin B; Animals; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Disease Models, Animal; Dose-Response Relationship, Drug; Echinocandins; Female; Fungal Proteins; Mice; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Proline; Solubility; Structure-Activity Relationship; Yeasts	2000

Article

Year

Total synthesis and antifungal evaluation of cyclic aminohexapeptides.

Bioorganic & medicinal chemistry, 2000, Volume: 8, Issue:7

The need for new therapies to treat systemic fungal infections continues to rise. Naturally occurring hexapeptide echinocandin B (1) has shown potent antifungal activity via its inhibition of the synthesis of beta-1,3 glucan, a key fungal cell wall component. Although this series of agents has been limited thus far based on their physicochemical characteristics, we have found that the synthesis of analogues bearing an aminoproline residue in the 'northwest' position imparts greatly improved water solubility (> 5 mg/mL). The synthesis and structure-activity relationships (SAR) based on whole cell and upon in vivo activity of the series of compounds are reported.

Topics: Acute Disease; Amines; Amphotericin B; Animals; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Disease Models, Animal; Dose-Response Relationship, Drug; Echinocandins; Female; Fungal Proteins; Mice; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Proline; Solubility; Structure-Activity Relationship; Yeasts

2000